Scaling up viral vector manufacturing with adherent and suspension cell culturesPublished: June 8, 2020
Adherent and suspension bioreactors for viral vector manufacturing are evolving. However, for each choice, a robust manufacturing process is critical to ensure it is scalable for these novel therapies to reach the patients.
One of the first steps in designing a process is whether to use adherent or suspension cell cultures. Each modality has its advantages and disadvantages. In this webinar, the panelists will outline key considerations in choosing the right technology and some of the pitfalls that must be overcome to ensure success at large scale.
- What factors to consider when choosing your cell culture
- The advantages and pitfalls with each type of culture
- The bioreactor choices available to support each type of culture
Clive Glover, Director, Strategy, Pall Corporation
Dr Clive Glover is the Director, Strategy at Pall Biotech where he leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.
Rachel Legmann, PhD, Director, Technical Consultancy, Gene Therapy & Viral Vectors, Pall Biotech
Rachel is partnering with sales, marketing and Pall’s technology teams to build company prominence as a preferred partner for the development and manufacturing of virus based therapeutics with a focus on Gene Therapy. In addition to supporting customers and building high level networks, Rachel is supporting various internal cross-functional activities including due diligence and new product development.
Rachel has more than 20 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vector and proteins for gene therapy and biologics. She completed her PhD in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Israel. Rachel joined Pall in 2014 serving as a process development services senior lab manager in charge of upstream and downstream process development, scale-up, and manufacturing support activities for the gene therapy and biologics markets. Prior to joining Pall, Rachel held several scientific and leadership roles at Microbiology & Molecular Genetics department at Harvard Medical School, SBH Sciences (CRO), Seahorse Biosciences-Agilent, and Goodwin Biotechnology (CMO).
Sid Gupta, Senior Bioprocess Applications Specialist, Pall Biotech
Sid is a Senior Bioprocess Applications Specialist within Pall Biotech’s Scientific and Laboratory Services Group. In this role, he acts as a technical consultant for biopharmaceutical manufacturing organizations aiming to scale up their production platforms to serve the Cell and Gene therapy industry.
Sid has 8 years of experience with cell and gene therapy, including positions in Process Development and Product Lifecycle Management at Juno Therapeutics and the Lonza Group. He has co-authored six peer reviewed articles, multiple book chapters, and holds one patent. Sid obtained his graduate and undergraduate degrees in Biomedical Engineering from the Johns Hopkins University and the Indian Institute of Technology, Guwahati, respectively. In his free time, he enjoys funk and hip-hop music and spending time outdoors in the PNW.